Pre-clinical work has identified ARID1A deficiency as a biomarker for the efficacy of ATR inhibitors, and in ovarian cancer cells, the multi-kinase inhibitor dasatinib [52, 53]. The gene discussed is ARID1A; the disease is ovarian cancer.